244
Views
4
CrossRef citations to date
0
Altmetric
Review

The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer’s disease clinical trials

, , &
Pages 767-775 | Received 29 Mar 2017, Accepted 08 Jun 2017, Published online: 19 Jun 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Kurt A. Jellinger. (2017) Potential clinical utility of multiple system atrophy biomarkers. Expert Review of Neurotherapeutics 17:12, pages 1189-1208.
Read now

Articles from other publishers (3)

Agathe Vrillon & Claire Paquet. (2022) Biomarqueurs de la maladie d’Alzheimer : des avancées très rapides. La Presse Médicale Formation 3:1, pages 49-56.
Crossref
Jianwei Yang, Longfei Jia, Yan Li, Qiongqiong Qiu, Meina Quan & Jianping Jia. (2021) Fluid Biomarkers in Clinical Trials for Alzheimer’s Disease: Current and Future Application. Journal of Alzheimer's Disease 81:1, pages 19-32.
Crossref
Antoine R. Trammell, Darius J. McDaniel, Malik Obideen, Maureen Okafor, Tiffany L. Thomas, Felicia C. Goldstein, Leslie M. Shaw & Ihab M. Hajjar. (2020) Perceived Stress is Associated with Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in African Americans with Mild Cognitive Impairment. Journal of Alzheimer's Disease 77:2, pages 843-853.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.